Cancer stem cell targeted therapy: progress amid controversies | Zendy

Tao Wang | Zendy; Sarah Shigdar | Zendy; Michael P. Gantier | Zendy; Yingchun Hou | Zendy; Li Wang | Zendy; Yong Li | Zendy; Hadi Al Shamaileh | Zendy; Wang Yin | Zendy; Shufeng Zhou | Zendy; Xinhan Zhao | Zendy; Wei Duan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cancer stem cell targeted therapy: progress amid controversies

Author(s) -

Tao Wang,

Sarah Shigdar,

Michael P. Gantier,

Yingchun Hou,

Li Wang,

Yong Li,

Hadi Al Shamaileh,

Wang Yin,

Shufeng Zhou,

Xinhan Zhao,

Wei Duan

Publication year - 2015

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.6176

Subject(s) - targeted therapy , medicine , stem cell , cancer therapy , stem cell therapy , cancer stem cell , cancer , oncology , cancer research , biology , transplantation , genetics

Although cancer stem cells have been well characterized in numerous malignancies, the fundamental characteristics of this group of cells, however, have been challenged by some recent observations: cancer stem cells may not necessary to be rare within tumors; cancer stem cells and non-cancer stem cells may undergo reversible phenotypic changes; and the cancer stem cells phenotype can vary substantially between patients. Here the current status and progresses of cancer stem cells theory is illustrated and via providing a panoramic view of cancer therapy, we addressed the recent controversies regarding the feasibility of cancer stem cells targeted anti-cancer therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research